1. Home
  2. CLPR vs SKYE Comparison

CLPR vs SKYE Comparison

Compare CLPR & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clipper Realty Inc.

CLPR

Clipper Realty Inc.

HOLD

Current Price

$2.95

Market Cap

51.8M

Sector

Real Estate

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.58

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPR
SKYE
Founded
2015
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.8M
44.9M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
CLPR
SKYE
Price
$2.95
$0.58
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$15.00
AVG Volume (30 Days)
66.6K
285.3K
Earning Date
05-11-2026
03-10-2026
Dividend Yield
12.58%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$109,997,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.82
N/A
52 Week Low
$2.97
$0.60
52 Week High
$4.61
$5.75

Technical Indicators

Market Signals
Indicator
CLPR
SKYE
Relative Strength Index (RSI) 35.99 32.30
Support Level N/A N/A
Resistance Level $3.96 $0.83
Average True Range (ATR) 0.12 0.05
MACD 0.00 -0.00
Stochastic Oscillator 10.29 1.06

Price Performance

Historical Comparison
CLPR
SKYE

About CLPR Clipper Realty Inc.

Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: